 JUPITER, FL ACCESSWIRE January 11, 2021 Dyadic International, Inc. Dyadic NASDAQ:DYAI, a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced the appointment of Patrick Lucy, to its Board of Directors, effective January 8, 2021. Mr. Lucy will serve as an independent director and a member of the Boards Science and Technology Committee. 